Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 16Carcinoma, Non-Small-Cell Lung 10Ovarian Neoplasms 6Endometrial Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Melanoma 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Stomach Neoplasms 2Rectal Neoplasms 2Osteosarcoma 2Neoplasm Metastasis 2Multiple Myeloma 2Lung Neoplasms 2Colonic Neoplasms 2Rhabdomyosarcoma 1Recurrence 1Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1Neuroblastoma 1Neoplasms by Site 1Hodgkin Disease 1Hepatoblastoma 1Glioblastoma 1Gastrointestinal Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Fallopian Tube Neoplasms 1Ependymoma 1Digestive System Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 80Nivolumab 60Sunitinib 59Sorafenib 36Everolimus 32pazopanib 30Axitinib 27cabozantinib 25Ipilimumab 24Bevacizumab 24atezolizumab 20belzutifan 19lenvatinib 16avelumab 13Paclitaxel 10Docetaxel 9temsirolimus 8Cyclophosphamide 8spartalizumab 7fludarabine 7Interleukin-2 7Interferon alpha-2 7tivozanib 6durvalumab 6Cetuximab 6cemiplimab 5aldesleukin 5Ramucirumab 5CB-839 5bempegaldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Renal Cell × dostarlimab × Clear all
NCT05277051 2026-05-22

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

GlaxoSmithKline

Phase 1 Active not recruiting
152 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡